Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Structure Of Human Pro-chymase: A Model For The Activating Transition Of Granule-associated Proteases.

K. K. Reiling, J. Krucinski, L. Miercke, W. Raymond, G. Caughey, R. Stroud
Published 2003 · Chemistry, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Human chymase is a protease involved in physiological processes ranging from inflammation to hypertension. As are all proteases of the trypsin fold, chymase is synthesized as an inactive "zymogen" with an N-terminal pro region that prevents the transition of the zymogen to an activated conformation. The 1.8 A structure of pro-chymase, reported here, is the first zymogen with a dipeptide pro region (glycine-glutamate) to be characterized at atomic resolution. Three segments of the pro-chymase structure differ from that of the activated enzyme: the N-terminus (Gly14-Gly19), the autolysis loop (Gly142-Thr154), and the 180s loop (Pro185A-Asp194). The four N-terminal residues (Gly14-Glu15-Ile16-Ile17) are disordered. The autolysis loop occupies a position up to 10 A closer to the active site than is seen in the activated enzyme, thereby forming a hydrogen bond with the catalytic residue Ser195 and occluding the S1' binding pocket. Nevertheless, the catalytic triad (Asp102-His57-Ser195) is arrayed in a geometry close to that seen in activated chymase (all atom rmsd of 0.52 A). The 180s loop of pro-chymase is, on average, 4 A removed from its conformation in the activated enzyme. This conformation disconnects the oxyanion hole (the amides of Gly193 and Ser195) from the active site and positions only approximately 35% of the S1-S3 binding pockets in the active conformation. The backbone of residue Asp194 is rotated 180 degrees when compared to its conformation in the activated enzyme, allowing a hydrogen bond between the main-chain amide of residue Trp141 and the carboxylate of Asp194. The side chains of residues Phe191 and Lys192 of pro-chymase fill the Ile16 binding pocket and the base of the S1 binding pocket, respectively. The zymogen positioning of both the 180s and autolysis loops are synergistic structural elements that appear to prevent premature proteolysis by chymase and, quite possibly, by other dipeptide zymogens.
This paper references



This paper is referenced by
Expression , Purification , and Characterization of the Mast Cell Proteases Chymase and Cathepsin
G. (2015)
10.1165/rcmb.2009-0324RT
Mast cell peptidases: chameleons of innate immunity and host defense.
N. Trivedi (2010)
10.1074/jbc.M109.012344
Stabilization of the E* Form Turns Thrombin into an Anticoagulant*
A. Bah (2009)
Biological function of mast cell chymase
E. Chugunova (2004)
10.1016/b978-0-12-385504-6.00004-x
Thrombin as an anticoagulant.
E. Di Cera (2011)
10.1016/j.bmcl.2011.05.126
Benzimidazolone as potent chymase inhibitor: modulation of reactive metabolite formation in the hydrophobic (P1) region.
H. Y. Lo (2011)
10.1016/B978-0-12-385504-6.00004-X
Thrombin as an anticoagulant.
E. Cera (2011)
10.1097/01.ASN.0000076125.12092.C6
Chymase: a potential culprit in diabetic nephropathy?
E. Ritz (2003)
10.1016/j.pep.2014.08.005
Expression of recombinant human mast cell chymase with Asn-linked glycans in glycoengineered Pichia pastoris.
Eliot T Smith (2014)
10.1007/978-1-60327-003-8_1
Delineating protease functions during cancer development.
N. I. Affara (2009)
10.1074/jbc.M109.069500
Mutant N143P Reveals How Na+ Activates Thrombin*
Weiling Niu (2009)
10.1016/S0065-2776(07)95006-3
Mast cell proteases.
G. Pejler (2007)
10.1124/pr.110.002733
Neutrophil Elastase, Proteinase 3, and Cathepsin G as Therapeutic Targets in Human Diseases
B. Korkmaz (2010)
10.1111/J.1472-9725.2004.00041.X
Genetic insights into mast cell chymase and tryptase function
G. Caughey (2004)
10.1097/01.crd.0000195220.62533.c5
Chymase: A New Pharmacologic Target in Cardiovascular Disease
C. Bacani (2006)
10.1016/J.BBAPAP.2004.09.005
Serine proteases and cardiac function.
Q. Wu (2005)
10.1002/iub.186
Serine proteases
E. Di Cera (2009)
10.1073/pnas.1010262107
Crystal structure of prethrombin-1
Zhiwei Chen (2010)
10.5530/ijper.54.3.99
Therapeutic Potential of Chymase Inhibitors in Cardiovascular Diseases: An Overview
Q. Aga (2020)
Expression, Purification, and Characterization of the Mast Cell Proteases Chymase and Cathepsin G.
B. E. Lockhart (2008)
10.1016/j.pharmthera.2018.05.011
Therapeutic targeting of cathepsin C: from pathophysiology to treatment
B. Korkmaz (2018)
10.20546/IJCMAS.2016.507.095
Role of Chymases in Human Biology: Significance, Mechanism and Functions
D.B.M. Virupakshaiah (2016)
Expressão e caracterização das quimases recombinantes específicas de mastócitos de camundongos (mMCP4 e 5)
Programa de Pós-graduação (2014)
10.2174/157339806778019024
A Pulmonary Perspective on GASPIDs: Granule-Associated Serine Peptidases of Immune Defense.
G. Caughey (2006)
Biological Function of Mast Cell Chymase In vitro and in vivo studies: a thorny pathway
E. Chugunova (2004)
10.1016/J.JMB.2007.02.032
Structural and mechanistic exploration of acid resistance: kinetic stability facilitates evolution of extremophilic behavior.
B. Kelch (2007)
10.1016/J.POLYMER.2004.03.039
Three-dimensional modeling of squamous cell carcinoma antigen 2 and its interactions with serine protease
Xue-feng Gao (2004)
10.1007/s11010-006-9342-0
Chymase increases glomerular albumin permeability via protease-activated receptor-2
R. Sharma (2006)
10.1515/bc.2010.047
Analysis of an engineered plasma kallikrein inhibitor and its effect on contact activation
A. A. Stoop (2010)
10.1016/j.bcp.2010.06.014
Potency variation of small-molecule chymase inhibitors across species.
J. Kervinen (2010)
10.1074/jbc.M304087200
Albumin Is a Substrate of Human Chymase
W. Raymond (2003)
10.1016/B978-0-12-382219-2.00590-1
Chapter 590 – Chymases
G. Caughey (2013)
See more
Semantic Scholar Logo Some data provided by SemanticScholar